Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
WEDNESDAY, 22 JULY, 2026
08:30 - 09:30
REGISTRATION AND MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES IN THE TREATMENT OF CHILDREN WITH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE)
Roxane Van Heurck
Hôpitaux Universitaires de Genève

Roxane Van Heurck

Hôpitaux Universitaires de Genève

  • Mapping diagnostic yields in paediatric DEE to identify candidates for ASO intervention
  • Prioritising actionable variants from common and ultra-rare genes using ASO strategy fit
  • Designing personalised ASOs via PACT partnerships to expand access across Europe safely
10:05 - 10:10
Q&A SESSION ON PERSONALISED ASO THERAPIES
10:10 - 10:40
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues ̶ don't forget your business cards!
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON MRNA CONFERENCE
11:30 - 11:55
ENABLING RAPID mRNA VACCINE DEVELOPMENT WITH CELL-FREE DNA TEMPLATES FOR PANDEMIC PREPAREDNESS
Anusha Dias
Sanofi

Anusha Dias

Sanofi

  • Replacing plasmids with cell-free DNA to speed IVT template supply without endotoxin risks
  • Optimising rolling circle amplification to yield long linear constructs with high sequence fidelity
  • Integrating enzymatic digestion and mRNA characterisation to cut timelines and improve flexibility
11:55 - 12:00
Q&A SESSION ON cfDNA TEMPLATES FOR RAPID MRNA VACCINES
12:00 - 13:30
NETWORKING LUNCH AND VISITING THE mRNA CONFERENCE EXHIBITION
13:30 - 13:55
MRNA SEQUENCE DESIGN AND mRNA-BASED IN VIVO CAR-T THERAPEUTICS
Zhongyao Ma
WuXi AppTec

Zhongyao Ma

WuXi AppTec

  • Designing combinatorial LNP libraries and screening candidates for in vivo delivery performance
  • Refining mRNA sequences and UTRs to improve expression, stability, and activity
  • Demonstrating in vivo CAR-T generation using mRNA-tLNPs through a focused case study programme
13:55 - 14:00
Q&A SESSION ON mRNA DESIGN FOR IN VIVO CAR-T THERAPEUTICS
14:00 - 14:25
ADVANCING RNA THERAPEUTICS WITH SENS™ POLYMER–LIPID HYBRID NANOPARTICLES
Yoojin Cho
Samyang Biopharm

Yoojin Cho

Samyang Biopharm

  • Deploying SENS™ hybrid nanoparticles for tissue-selective RNA therapeutic delivery
  • Engineering biodegradable polymer and ionisable lipid cores to balance potency and safety
  • Targeting spleen, lung, muscle, CNS and liver while supporting repeat dosing profiles
14:25 - 14:30
Q&A SESSION ON HYBRID NANOPARTICLES FOR RNA DELIVERY
14:30 - 15:00
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:00 - 15:25
THERAPEUTIC NUCLEIC ACIDS - ADVANCED SOLUTIONS FOR DOWNSTREAM PROCESSING AND ANALYTICS
Elena Kumm
Tosoh Bioscience GmbH

Elena Kumm

Tosoh Bioscience GmbH

  • Refining chromatographic methods tailored for high purity therapeutic oligonucleotides
  • Purifying across impurity classes from shortmers and longmers to process related contamin
  • Profiling case studies to guide strategy selection and optimisation for robust downstream workflows
15:25 - 15:30
Q&A SESSION ON OLIGO DOWNSTREAM PROCESSING AND ANALYTICS
15:30 - 16:00
RESERVED PRESENTATION
16:00 - 17:00
NETWORKING DRINKS RECEPTION
Day 2 :
THURSDAY, 23 JULY, 2026
09:00 - 09:30
MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
INTRANASAL mRNA VACCINE: TARGETING THE FRONT LINES OF RESPIRATORY VIRUS DEFENCE
Sudha Chivukula
Sanofi

Sudha Chivukula

Sanofi

  • Protecting airways by inducing mucosal immunity where respiratory viruses first replicate
  • Eliciting robust pulmonary immune responses through intranasal dosing beyond traditional injections
  • Reducing influenza and RSV viral loads across species to help stop infection at the source
10:05 - 10:10
Q&A SESSION ON INTRANASAL mRNA VACCINES
10:10 - 10:35
PATENT STRATEGY FOR RNA THERAPEUTICS IN EUROPE AND THE US
Ross Cummings
Gill Jennings & Every LLP

Ross Cummings

Gill Jennings & Every LLP

  • Clarifying EU and US patent eligibility boundaries for RNA sequences and modification
  • Structuring claim strategies across RNA types, using sequence plus chemistry combinations
  • Evidencing inventions with the right experimental data, knowing when and what to show
10:35 - 10:40
Q&A SESSION ON PATENT STRATEGY FOR RNA THERAPEUTICS
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:25
EXPANDING THE USES OF mRNA THERAPEUTICS BEYOND INFECTIOUS DISEASE
Christine Duthoit
RNAlead

Christine Duthoit

RNAlead

  • Overcoming delivery barriers to broaden mRNA therapeutics beyond classical targets
  • Exploring hybrid nanoparticles as next-generation RNA carriers for therapeutic delivery
  • Linking insights from novel delivery systems to translational therapeutic applications
11:25 - 11:30
Q&A SESSION ON EXPANDING mRNA BEYOND INFECTIONS
11:30 - 11:55
NEXT GENERATION MRNA NANOPARTICLES FOR VACCINATION AND THERAPY
Heinrich Haas
NeoVac

Heinrich Haas

NeoVac

  • Upgrading NeoVac lipids to improve safety, immunogenicity, and CMC versus current LNPs
  • Resolving delivery limits to enable a broader range of mRNA vaccines and therapeutics
  • Validating Phase I/II results showing safer profiles than licensed mRNA products in humans
11:55 - 12:00
Q&A SESSION ON NEXT-GEN NANOPARTICLES FOR MRNA DELIVERY
12:00 - 12:25
FROM IND TO MARKET: REGULATORY STRATEGY AND COMPLIANCE PITFALLS IN mRNA CLINICAL DEVELOPMENT
Yassin Somoue Chafik
Universidad d Salamanca

Yassin Somoue Chafik

Universidad d Salamanca

  • Navigating EMA and FDA expectations from preclinical work through IND or CTA filings
  • Identifying CMC and potency assay bottlenecks that delay comparability across platforms
  • Interpreting post-COVID regulatory shifts shaping accelerated pathways for mRNA approvals
12:25 - 12:30
Q&A SESSION ON COMPLIANCE PITFALLS IN mRNA DEVELOPMENT
12:30 - 12:45
FEEDBACK AND RAFFLE DRAW
12:45 - 14:00
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.